Fig. 3.

Correlation of remission duration with serine 21/9 GSK 3α/β phosphorylation levels in AML patient cytogenetic subsets. The Kaplan–Meier curve for remission duration for the total treated AML patient set (A; N = 231), treated intermediate cytogenetic patient set (B; N = 120), and treated intermediate cytogenetic with the FLT3 mutant patient set (C; N = 35) based on expression of phosphorylated GSK3α/β.